U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344558) titled 'A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis' on Jan. 07.
Brief Summary: MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.
Study Start Date: Dec. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Idiopathic Pulmonary Fibrosis (IPF)
Intervention:...